Coherus Oncology (NASDAQ:CHRS) Releases Earnings Results, Misses Expectations By $0.03 EPS

Coherus Oncology (NASDAQ:CHRS) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03), Zacks reports. The company had revenue of $14.27 million for the quarter, compared to analyst estimates of $15.90 million. Coherus Oncology had a negative net margin of 259.41% and a negative return on equity of 222.75%.

Here are the key takeaways from Coherus Oncology’s conference call:

• Coherus is concentrating tagmokitug development on esophageal cancer after seeing early activity with tagmokitug plus LOQTORZI: in nine evaluable second-line patients, confirmed response rate was 33%, with additional unconfirmed responses. The company plans to discuss dose and trial design with the FDA in early 2027, including whether a randomized study could support accelerated approval; the data remain preliminary.
• The company is targeting a roughly 30% headcount reduction and expects recurring cost savings of $6 million–$7 million per quarter, lowering the LOQTORZI revenue needed to cover core costs from $30 million–$35 million to $25 million–$30 million per quarter. Most savings are expected within two quarters, while substantially preserving the commercial team.
• LOQTORZI sales were $14 million, up 3% sequentially but below the company’s 10%–15% growth target amid slower patient starts in some territories. Coherus expects $54 million–$57 million in 2026 revenue and still projects $15 million in Q4; it cited market share of about 20%–22% and opportunities to displace chemotherapy-only and off-label immunotherapy use.
• Coherus ended Q3 with $83.6 million in cash and investments, and reported $34 million of operating cash use. The company disclosed that its cash runway is less than 12 months from the 10-Q filing date, excluding potential cost savings, an earnout payment, or ex-U.S. partnering proceeds.

Coherus Oncology Price Performance

Shares of NASDAQ CHRS opened at $0.82 on Tuesday. The stock has a market cap of $126.32 million, a price-to-earnings ratio of -0.79 and a beta of 1.03. Coherus Oncology has a 52 week low of $0.73 and a 52 week high of $2.62. The company’s 50-day moving average price is $1.12 and its 200 day moving average price is $1.50. The company has a current ratio of 1.77, a quick ratio of 1.70 and a debt-to-equity ratio of 0.61.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on CHRS shares. HC Wainwright began coverage on Coherus Oncology in a report on Thursday, October 29th. They issued a “buy” rating on the stock. Weiss Ratings raised Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 26th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $11.00.

Coherus Oncology Company Profile

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.